MYOV - Myovant's Uterine Fibroid Drug Relugolix Produces Positive Data in a Long-Term Study
Myovant Sciences (NYSE: MYOV) reported positive results from the late-stage Liberty extension study testing its relugolix combination therapy, which contains relugolix, estradiol, and norethindrone acetate, in patients with uterine fibroids.
The biotech had already successfully tested relugolix in two pivotal clinical trials -- dubbed Liberty 1 and 2 -- but those studies only tested how patients responded to the drug for 24 weeks. Since the combination therapy may not be a cure, Myovant Sciences allowed patients from those two studies to enter this extension study, testing it for a total of 52 weeks.
After a year of treatment, 87.7% of the women had responded to the therapy. The drug produced an 89.9% average reduction in menstrual blood loss from baseline.